Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01068158
Other study ID # TOP012
Secondary ID
Status Completed
Phase Phase 3
First received February 11, 2010
Last updated April 4, 2012
Start date March 2010
Est. completion date July 2010

Study information

Verified date April 2012
Source Topaz Pharmaceuticals Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.


Recruitment information / eligibility

Status Completed
Enrollment 371
Est. completion date July 2010
Est. primary completion date June 2010
Accepts healthy volunteers No
Gender Both
Age group 5 Months and older
Eligibility Inclusion Criteria:

- Index subjects must have an active head lice infestation defined as: At least 3 live lice (adults and/or nymphs) present on the scalp and/or hair, as determined by a trained evaluator. The index subject must be the youngest family member presenting with at least 3 live lice. After the index subject has been identified, additional infested household members (see b below) will be enrolled.

- Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and/or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self-assess as being lice free).

- Subject is male or female.

- Subject is at least 6 months of age at time of enrollment.

- Subject is in good general health based on medical history.

- Each subject must have an appropriately signed Informed Consent agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form.

- The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, according to the criteria b (above), they must be willing and able to participate in the study. No more than one working male per household may be excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility; otherwise the entire household will be excluded from study participation.

- Subject and/or their caregiver must be physically able and willing to apply the test article.

- Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while participating in the study.

- Following application and rinsing of the test article, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24-hour post-treatment evaluation has been completed.

- Subject agrees to not cut or chemically treat their hair while participating in the study.

- Subject agrees to follow all study instructions.

- Female subjects of childbearing potential (including a female caregiver even if she is not being treated) must be willing to have a urine pregnancy test.

- In the event of a subject judged to be incapable of self-treating, the household must have a caregiver willing to apply the treatment at home.

Exclusion Criteria:

- History of irritation or sensitivity to ivermectin or the cream components, pediculicides or hair care products.

- Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or sponsor, will interfere with safety and/or efficacy evaluations.

- Presentation at the treatment site with eczema or atopic dermatitis.

- Treatment for head lice (over-the-counter [OTC], home remedy and/or Prescription) in the last 7 days.

- Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol.

- Is receiving any other treatment which, in the opinion of the investigator or study monitor, may interfere with the study results.

- Females (including caregivers who come in contact with the investigational product) who are pregnant, nursing or planning a pregnancy. (NOTE: female caregivers and all enrolled females of childbearing potential must have a negative urine pregnancy test prior to treatment). If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation. If this pregnant household member does not have an active infestation, this individual must NOT be the caregiver (one who provides treatment to other household members).

- Is of child-bearing potential and unwilling to use an adequate method of contraception for the duration of the study. Adequate methods of contraception include: abstinence, vasectomized partner, oral birth control pills, birth control injections or patches, intrauterine device, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilization.

- Participation in a previous investigational drug study within the past 30 days.

- Prior participation in any ivermectin trials.

- Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator.

- Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house or apartment unit).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
0.5% Ivermectin Cream
Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
Placebo control
up to 4 ounces of topical vehicle control to head and scalp on day 1.

Locations

Country Name City State
United States Lovelace Scientific Resources, Inc. Albuquerque New Mexico
United States Haywood Pediatric and Adolescent Medicine Group, PA Clyde North Carolina
United States Lice Cleanique, LLC Delray Beach Florida
United States Northeast Houston Pediatric Clinic Houston Texas
United States Arkansas Pediatric Clinic Little Rock Arkansas
United States LSRN Nashville Tennessee
United States Hill Top Research St Petersburg Florida

Sponsors (1)

Lead Sponsor Collaborator
Topaz Pharmaceuticals Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) Treatment success, defined as absence of live lice, was assessed in index subjects, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation. Day 2 up to Day 15 post-application No
Primary Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation. Day 2 up to Day 15 post-application No
Secondary Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control) Adverse events were defined and classified as follows:
'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.
Day 2 up to Day 15 post-application No
Secondary Summary of the Reported Skin/Scalp Irritation Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control) Severe skin/scalp irritations were defined as follows:
Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
Day 2 up to Day 15 post-application No
See also
  Status Clinical Trial Phase
Completed NCT00988533 - A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age Phase 1
Completed NCT00672971 - Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice N/A
Completed NCT00858481 - A Pilot Dose Ranging Study of Spinosad Creme Rinse Phase 2
Completed NCT03301649 - Clinical Endpoint Study of Ivermectin 0.5% Lotion Phase 3
Completed NCT00995124 - Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application Phase 4
Completed NCT00994422 - Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects Phase 2
Completed NCT03337490 - A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice Phase 3
Completed NCT06333054 - Safety and Efficacy of a Head Lice Shampoo N/A
Completed NCT02213055 - Pediatric Head Lice Study Product Comparison Phase 2
Completed NCT02974088 - Neem Lotion With Combing for Lice Phase 2
Recruiting NCT05379114 - Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation N/A
Completed NCT03617926 - A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product. N/A
Completed NCT01803581 - A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice N/A
Completed NCT01066585 - A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation Phase 3
Completed NCT00857935 - A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse Phase 2
Completed NCT00301340 - Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice Phase 3
Completed NCT02062073 - Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion Phase 1
Completed NCT02061813 - Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion Phase 1
Completed NCT00605956 - NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers Phase 1
Completed NCT00479310 - Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice Phase 3